An Open-Label, Phase 2 Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2018.05.022
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Diffuse Large B-Cell Lymphoma Presenting in the Leukemic Phase

Autopsy and Case Reports
2016English

Diffuse Large B-Cell Lymphoma

2020English

Mocetinostat for Relapsed Classical Hodgkin's Lymphoma: An Open-Label, Single-Arm, Phase 2 Trial

The Lancet Oncology
Oncology
2011English

Phase II Open Label Study of the Oral Vascular Endothelial Growth Factor-Receptor Inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients With Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2013English

B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Seminars in Hematology
Hematology
2015English

Diffuse Large B-Cell Lymphoma: A Case Report

Clinical and Experimental Health Sciences
2018English

Epigenetic Silencing of TFPI-2 in Canine Diffuse Large B-Cell Lymphoma

PLoS ONE
Multidisciplinary
2014English

ALK -Positive Diffuse Large B-Cell Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy